期刊
BEHAVIOR GENETICS
卷 37, 期 1, 页码 119-145出版社
SPRINGER
DOI: 10.1007/s10519-006-9115-2
关键词
polymorphism; drug response; microarray; disulfiram; cAMP; CREB; transduction; intracellular; addiction; genetic models; inbred rats; mesolimbic; DBH; pharmacotherapies; epigenetics; gene expression
资金
- NIDA NIH HHS [P50-DA018197, K05-DA00454] Funding Source: Medline
- NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000454, P50DA018197] Funding Source: NIH RePORTER
Cocaine addiction is a major health and social problem for which there are presently no effective pharmacotherapies. Many of the most promising medications target dopamine based on the large literature that supports its role in addiction. Recent studies show that genetic factors are also important. Rodent models and gene knock-out technology have helped elucidate the involvement of specific genes in the function of the dopamine reward system and intracellular cascades that lead to neuronal changes in this system. Human epidemiological, linkage, and association studies have identified allelic variants (polymorphisms) that give rise to altered metabolism of dopamine and its functional consequences. Individuals with these polymorphisms respond differently to psychostimulants and possibly to pharmacotherapies. Here we review the literature on genetic variations that affect dopamine neurotransmission, responses to psychostimulants and potential treatments for cocaine addiction. Behavioral responses to psychostimulants in animals with different or modified genetics in dopamine signaling are discussed. We also review polymorphisms in humans that affect dopaminergic neurotransmission and alter the subjective effects of psychostimulants. Pharmacotherapies may have increased efficacy when targeted to individuals possessing specific genetic polymophisms in dopamine's metabolic and intracellular messenger systems.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据